HPR24 Critical Analysis on Time-to-Reimbursement of Rare Disease Drugs: The Italian Case (AIFA Commissions 2018-2022)
Dec 1, 2022, 00:00
10.1016/j.jval.2022.09.1156
https://www.valueinhealthjournal.com/article/S1098-3015(22)03361-7/fulltext
Title :
HPR24 Critical Analysis on Time-to-Reimbursement of Rare Disease Drugs: The Italian Case (AIFA Commissions 2018-2022)
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)03361-7&doi=10.1016/j.jval.2022.09.1156
First page :
Section Title :
Open access? :
No
Section Order :
10705